Kiromic BioPharma (NASDAQ:KRBP) Posts Quarterly Earnings Results

Kiromic BioPharma (NASDAQ:KRBPGet Free Report) issued its quarterly earnings results on Friday. The company reported ($1.00) EPS for the quarter, reports.

Kiromic BioPharma Trading Down 0.4 %

Shares of NASDAQ:KRBP opened at $2.40 on Monday. The company has a 50-day moving average price of $2.57 and a two-hundred day moving average price of $1.64. Kiromic BioPharma has a twelve month low of $0.16 and a twelve month high of $5.49.

About Kiromic BioPharma

(Get Free Report)

Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.

See Also

Earnings History for Kiromic BioPharma (NASDAQ:KRBP)

Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.